1-甲基-1H-咪唑-5-硼酸频那醇酯 | 942070-72-6

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-1H-咪唑-5-硼酸频那醇酯
• 中文别名: 1-甲基-1-H-咪唑-5-硼酸频那醇酯
• 英文名称: 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole
• 英文别名: 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazole；1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole；1-methyl-1H-imidazole-5-boronic acid pinacol ester；1-methylimidazole-5-boronic acid pinacol ester
• CAS: 942070-72-6
• 化学式: C₁₀H₁₇BN₂O₂
• 分子量: 208.068
• InChiKey: SNKPPKAANOYIRX-UHFFFAOYSA-N

物化性质

• 沸点：
  352.0±15.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-咪唑-5-硼酸频那醇酯 、 2-chloro-7-cyclopentyl-6-iodo-7H-pyrrolo[2,3-d]pyrimidine 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-7-cyclopentyl-6-(1-methyl-1H-imidazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors

  摘要：

  This Letter reports the optimization of a pyrrolopyrimidine series as dual inhibitors of Aurora A/B kinases. This series derived from a pyrazolopyrimidine series previously reported as inhibitors of aurora kinases and CDKs. In an effort to improve the selectivity of this chemotype, we switched to the pyrrolopyrimidine core which allowed functionalization on C-2. In addition, the modeling rationale was based on superimposing the structures of Aurora-A kinase and CDK2 which revealed enough differences leading to a path for selectivity improvement. The synthesis of the new series of pyrrolopyrimidine analogs relied on the development of a different route for the two key intermediates 7 and 19 which led to analogs with both tunable activity against CDK1 and maintained cell potency. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.085
• 作为产物：
  描述：

  N-甲基咪唑 、 联硼酸频那醇酯 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 C₅₂H₃₄N₈Zn 、 频那醇硼烷 作用下， 以 对二甲苯 为溶剂， 以90 %的产率得到1-甲基-1H-咪唑-5-硼酸频那醇酯
  参考文献：
  名称：

  使用超分子铱催化剂快速选择性地对 N-杂环进行 β-C-H 硼酸化：规避失活途径和机理见解

  摘要：

  选择性铱催化的无偏向或无导向基团底物的 C-H 键硼酸化通常发生在长反应时间和温和温度下，以避免包括催化剂失活在内的非选择性过程。在此，我们描述了一种超分子方法，该方法能够在非常短的反应时间（最多 2 小时）内实现具有挑战性的吡啶和咪唑的 C-H 键硼酸化，而催化剂活化的潜伏期可忽略不计。该催化剂基于二级配位球中的高刚性锌卟啉底物识别位点和附着在铱第一配位球上的三唑并吡啶螯合片段。有_ _- 配位到铱的螯合片段，进一步得到密度泛函理论 (DFT) 计算的支持。其他研究（对照实验、核磁共振和单晶 X 射线衍射）揭示了关键的催化剂失活途径，其中多达三种不同的伙伴（水、来自铱前体的甲醇盐配体和三唑并吡啶片段）与 N 竞争-用于与超分子催化剂的分子识别位点结合的杂环底物。这种基本理解使得在铱的第一个配位层中具有 4-甲基取代模式的超分子催化剂的鉴定成为可能，该催化剂在一级和二级配位层中提供了空间和

  DOI：

  10.1021/acscatal.3c01742

文献信息

• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• [EN] BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS<br/>[FR] DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019149657A1

  公开（公告）日：2019-08-08

  The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及一般式（I）的化合物，其中基团R1和R2的定义如权利要求1中所述，该化合物具有有价值的药理特性，特别是与胃饥饿素O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• [EN] TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA<br/>[FR] COMPOSÉS DE TÉTRALINE ET DE TÉTRAHYDROQUINOLINE UTILISÉS EN TANT QU'INHIBITEURS DE HIF-2 ALPHA
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2021188769A1

  公开（公告）日：2021-09-23

  Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2a.

  抑制HIF-2a的化合物，以及包含该化合物的方法和合成化合物的方法都在这里描述。还描述了使用这些化合物和组合物治疗多种疾病、障碍和状况，包括至少部分由HIF-2a介导的癌症和免疫相关障碍。
• FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
  申请人：GRUNENTHAL GMBH

  公开号：US20140066426A1

  公开（公告）日：2014-03-06

  The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及带有氟甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS
  申请人：AbbVie Inc.

  公开号：US20150225397A1

  公开（公告）日：2015-08-13

  The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

  本申请涉及：(a) 公式(I)的化合物及其盐，其中R1、R2、R3、R4、R5、R6、m、n、X和Y如规范中定义；(b) 包含这些化合物和盐的组合物；以及(c) 这些化合物、盐和组合物的使用方法，特别是用于治疗和预防与氧化应激和炎症相关的疾病。